

PERSONAL INFORMATION

Bianchessi Antonio

Sex Male | Date of birth 12/04/1988 | Nationality Italian

EDUCATION AND TRAINING

12/11/2019

Specialization in Hematology

Specialization in Hematology obtained with a thesis entitled:

"Efficacy and safety of reduced vs full dose post-transplantation cyclophosphamide in patients with history of cardiac dysfunction or over 65 years old undergoing haploidentical alloHSCT: a monocentric experience in Saint-Antoine Hospital Paris"

Final vote: 50/50 cum laude

01/10/2019–Present

PhD student in Translational Medicine

University of Pavia, Pavia (Italy)

30/04/2019–Present

Clinical and research experience in the Transplant Center directed by prof. Mohamed Mohty

Saint Antoine Hospital- Pôle d'Oncologie-Hématologie Service d'Hématologie Clinique et de Thérapie Cellulaire, Paris (France)

12/2014–12/11/2019

Trainee in Haematology

University of Pavia, Pavia (Italia)

School of Specialization in Haematology

-ward activities of about two years (training in diagnostic and therapeutic pathways, management of the haematological patient , execution of invasive procedures such as bone marrow biopsies and aspirations, lumbar punctures);

- one year experience at the bone marrow Transplant Center, both in and outpatients (follow-up of the transplant recipients, pre- and post-transplant clinical management);

-general haematological outpatient activities (specially myelodysplastic syndromes and myelodysplastic/myeloproliferative disorders);

- one month's experience at the immuno-hematological and transfusion medicine center, at the pediatric onco-hematological outpatient clinic and at the hemostasis and thrombosis outpatient clinic

23/02/2016

BLS-D (Basic Life Support and Defibrillation)

IRC-Italian Resuscitation Council, Pavia (Italia)

25/02/2014

Registration to the State medical board

Ordine dei medici chirurghi di Pavia, Pavia (Italia)

31/07/2013

Medicine and Surgery degree

University of Pavia, Pavia (Italia)

Degree in Medicine and Surgery obtained with a thesis entitled: "Significato prognostico dello score IPSS-REVISED in pazienti affetti da Sindrome Mielodisplastica trattati con Trapianto Allogeneico di Cellule Staminali Emopoietiche" ("Prognostic Significance of IPSS-REVISED in patients affected by Myelodysplastic Syndrome treated with Haematopoietic Stem Cells Transplantation")

Final vote: 110/110 cum laude

Relatore: Prof. Mario Cazzola

10/07/2007 **High School Degree**
Liceo Classico "A. Racchetti", Crema (Italia)

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2
French	C1	C1	B2	B2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Digital skills good experience with Office Package

ADDITIONAL INFORMATION

Publications - Bono E, McLornan D, Travaglino E, Gandhi S, Galli A, Khan AA, Kulasekararaj AG, Boveri E, Raj K, Elena C, Ireland RM, **Bianchessi A**, Jiang J, Todisco G, Ferretti VV, Cazzola M, Marsh JCW, Malcovati L, Mufti GJ. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. *Leukemia*. 2019 Apr 2;. doi: 10.1038/s41375-019-0457-1. PubMed PMID: 30940907.

-Luca Malcovati, Anna Galli, Erica Travaglino, Ilaria Ambaglio, Ettore Rizzo, Elisabetta Molteni, Chiara Elena, Virginia Valeria Ferretti, Silvia Catricalà, Elisa Bono, Gabriele Todisco, **Antonio Bianchessi**, Elisa Rumi, Silvia Zibellini, Daniela Pietra, Emanuela Boveri, Clara Camaschella, Toniolo D, Elli Papaemmanuil, Seishi Ogawa, Mario Cazzola. Clinical significance of somatic mutation in unexplained blood cytopenia. *Blood*. 2017 Jun 22;129(25):3371-3378. doi: 10.1182/blood-2017-01-763425. Epub 2017 Apr 19.

Projects Sub-Investigator in Clinical Trials about Myelodysplastic syndromes, Chronic Myeloid Leukemia and Bone Marrow Transplantation (8)

- **MEDI-4736-MDS-001**: *Studio di Fase 2, randomizzato, multicentrico, in aperto per valutare l'efficacia e la sicurezza di azacitidina sottocutanea somministrata in combinazione con durvalumab (MEDI4736) in soggetti con sindrome mielodisplastica (MDS) ad alto rischio non precedentemente trattati o in soggetti anziani (>= 65 anni) con leucemia mieloide acuta (AML) non eleggibili al trapianto con cellule staminali ematopoietiche (HSCT). In delegation since 19/09/2016. Sponsor: Celgene International S.r.l*

- **ACE-536-MDS-001**: *A phase 3, double-blind, randomized study to compare the efficacy and safety of Luspatercept versus placebo for the treatment of anemia due to very low to intermediate risk myelodysplastic syndromes (MDS) in subjects with ring sideroblasts who require red blood cell (RBC) transfusions. In delegation since 22/06/2016. Sponsor: Celgene International S.r.l*

- **AZA-MDS-003**: *Studio di fase 3, multicentrico, randomizzato, in doppia cecità, che si propone di confrontare l'efficacia e la sicurezza dell'azacitidina orale somministrata insieme alla miglior terapia di supporto con il placebo somministrato insieme alla migliore terapia di supporto a soggetti con anemia trasfusione-dipendente e trombocitopenia causate da sindromi mielodisplastiche a più basso rischio secondo l'IPSS. In delegation since 09/11/2016. Sponsor: Celgene International S.r.l*

- **INCB 39110-301**: *GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease. In delegation since 26/06/2018. Sponsor: Incyte Corporation.*

- **CAMN107AIC05**: *A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different*

durations of consolidation treatment with nilotinib 300mg BID. In delegation since 23/09/2015.

Sponsor: Novartis Farma S.p.A

- **GIMEMA CML1315 (OPUS):** Studio GIMEMA di fase 2 sull'efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, che falliscono l'Imatinib. In delegation since 25/10/2016. Promotore: **Fondazione GIMEMA Onlus.**

- **CINC424D2301:** A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3). In delegation since 13/04/2017. **Sponsor: Incyte Corporation**

- **BMS SIMPLICITY CA180-330:** Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-World Setting (SIMPLICITY). In delegation since 01/10/2016. **Sponsor: Bristol-Myers Squibb**

Abstracts

- Elisa Bono, Donal McLornan, Erica Travaglino, Shreyans Gandhi, Anna Galli, Alesia Abigael Khan, Austin G. Kulasekararaj, Emanuela Boveri, Kavita Raj, Chiara Elena, Robin M. Ireland, **Antonio Bianchessi**, Jie Jiang, Gabriele Todisco, Luca Malcovati, Judith Marsh, Mario Cazzola and Ghulam Mufti. Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization. Blood 2017 130:588.

- Luca Malcovati, Anna Galli, Cinzia F Sala, Ettore Rizzo, Elisabetta Molteni, Silvia Zibellini, Eulalia Catamo, Erica Travaglino, Silvia Catricalà, Chiara Elena, Gabriele Todisco, Elisa Bono, **Antonio Bianchessi**, Virginia Valeria Ferretti, Paolo Gasparini, Clara Camaschella, Daniela Toniolo and Mario Cazzola. Prevalence of Clonal Hematopoiesis and Mutation Patterns in Unexplained Anemia of Community-Dwelling Elderly Individuals: A Casw-Control Study. Blood 2017; 130:1684.

- Chiara Elena, Anna Galli, **Antonio Bianchessi**, Virginia Valeria Ferretti, Silvia Zibellini, Silvia Catricalà, Celeste Calvello, Barbara Rocca, Paolo Bernasconi, Ettore Rizzo, Elisabetta Molteni, Luca Malcovati, Matteo Giovanni Della Porta, Ester Maria Orlandi and Mario Cazzola. Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors. Blood 2016 128:1117.

- Luca Malcovati, Anna Galli, Erica Travaglino, Ilaria Ambaglio, Ettore Rizzo, Elisabetta Molteni, Chiara Elena, Silvia Catricalà, Elisa Bono, **Antonio Bianchessi**, Gabriele Todisco, Elisa Rumi, Virginia Valeria Ferretti, Elli Papaemmanuil, Seishi Ogawa, and Mario Cazzola. Predictive Value of Mutation Analysis in the Diagnostic Approach to Patients with Unexplained Cytopenia. Blood 2016;128:298